Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia

Eight-week randomized, single-blind, placebo-controlled, multicenter study

Moon-Soo Lee, Hyun Cheol Song, Hyonggin An, Jaewon Yang, Young-Hoon Ko, In Kwa Jung, Sook Haeng Joe

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Aim: The objective of the present study was to assess the efficacy and safety of bromocriptine treatment for patients with antipsychotic-drug-induced hyperprolactinemia in clinical practice. Methods: This was an 8-week randomized, single-blind, placebo-controlled, multicenter study. Sixty female schizophrenia patients were enrolled and were randomly assigned to one of four treatment groups: bromocriptine 2.5 mg/day, 5 mg/day, 10 mg/day, and placebo. Serum levels of prolactin, estradiol (E2), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were evaluated on three occasions (baseline, and 4 and 8 weeks after commencement of the treatment paradigm). Extrapyramidal symptoms (EPS) and clinical symptoms were assessed using the Simpson-Angus scale and the Positive and Negative Syndrome Scale (PANSS), respectively. Results: Of the 60 subjects who were enrolled, 48 completed the study (n = 14, 13, 11, and 10 in the bromocriptine 2.5 mg/day, 5 mg/day, and 10 mg/day, and placebo groups, respectively). Four patients in the 10-mg/day group, two in the 5-mg/day group, and one in the placebo group resumed menses during the study. The mean level of prolactin significantly decreased from baseline to week 4, and then plateaued, showing no significant change for the remaining 4 weeks of the study. No significant changes in LH, FSH, or E2 levels were observed throughout the 8-week study period, either within or between groups. Conclusion: Administration of bromocriptine is a safe method for treating antipsychotic-drug-induced hyperprolactinemia without exacerbating either psychotic symptoms or EPS.

Original languageEnglish
Pages (from-to)19-27
Number of pages9
JournalPsychiatry and Clinical Neurosciences
Volume64
Issue number1
DOIs
Publication statusPublished - 2010 Feb 1

Fingerprint

Hyperprolactinemia
Bromocriptine
Antipsychotic Agents
Multicenter Studies
Placebos
Follicle Stimulating Hormone
Luteinizing Hormone
Prolactin
Menstruation
Estradiol
Schizophrenia
Therapeutics
Safety
Serum

Keywords

  • Amenorrhea
  • Antipsychotics
  • Bromocriptine
  • Hyperprolactinemia
  • Prolactin

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia : Eight-week randomized, single-blind, placebo-controlled, multicenter study. / Lee, Moon-Soo; Song, Hyun Cheol; An, Hyonggin; Yang, Jaewon; Ko, Young-Hoon; Jung, In Kwa; Joe, Sook Haeng.

In: Psychiatry and Clinical Neurosciences, Vol. 64, No. 1, 01.02.2010, p. 19-27.

Research output: Contribution to journalArticle

@article{1e5e29dced5d4ffaa6c0509d2e37cb40,
title = "Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: Eight-week randomized, single-blind, placebo-controlled, multicenter study",
abstract = "Aim: The objective of the present study was to assess the efficacy and safety of bromocriptine treatment for patients with antipsychotic-drug-induced hyperprolactinemia in clinical practice. Methods: This was an 8-week randomized, single-blind, placebo-controlled, multicenter study. Sixty female schizophrenia patients were enrolled and were randomly assigned to one of four treatment groups: bromocriptine 2.5 mg/day, 5 mg/day, 10 mg/day, and placebo. Serum levels of prolactin, estradiol (E2), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were evaluated on three occasions (baseline, and 4 and 8 weeks after commencement of the treatment paradigm). Extrapyramidal symptoms (EPS) and clinical symptoms were assessed using the Simpson-Angus scale and the Positive and Negative Syndrome Scale (PANSS), respectively. Results: Of the 60 subjects who were enrolled, 48 completed the study (n = 14, 13, 11, and 10 in the bromocriptine 2.5 mg/day, 5 mg/day, and 10 mg/day, and placebo groups, respectively). Four patients in the 10-mg/day group, two in the 5-mg/day group, and one in the placebo group resumed menses during the study. The mean level of prolactin significantly decreased from baseline to week 4, and then plateaued, showing no significant change for the remaining 4 weeks of the study. No significant changes in LH, FSH, or E2 levels were observed throughout the 8-week study period, either within or between groups. Conclusion: Administration of bromocriptine is a safe method for treating antipsychotic-drug-induced hyperprolactinemia without exacerbating either psychotic symptoms or EPS.",
keywords = "Amenorrhea, Antipsychotics, Bromocriptine, Hyperprolactinemia, Prolactin",
author = "Moon-Soo Lee and Song, {Hyun Cheol} and Hyonggin An and Jaewon Yang and Young-Hoon Ko and Jung, {In Kwa} and Joe, {Sook Haeng}",
year = "2010",
month = "2",
day = "1",
doi = "10.1111/j.1440-1819.2009.02032.x",
language = "English",
volume = "64",
pages = "19--27",
journal = "Psychiatry and Clinical Neurosciences",
issn = "1323-1316",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia

T2 - Eight-week randomized, single-blind, placebo-controlled, multicenter study

AU - Lee, Moon-Soo

AU - Song, Hyun Cheol

AU - An, Hyonggin

AU - Yang, Jaewon

AU - Ko, Young-Hoon

AU - Jung, In Kwa

AU - Joe, Sook Haeng

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Aim: The objective of the present study was to assess the efficacy and safety of bromocriptine treatment for patients with antipsychotic-drug-induced hyperprolactinemia in clinical practice. Methods: This was an 8-week randomized, single-blind, placebo-controlled, multicenter study. Sixty female schizophrenia patients were enrolled and were randomly assigned to one of four treatment groups: bromocriptine 2.5 mg/day, 5 mg/day, 10 mg/day, and placebo. Serum levels of prolactin, estradiol (E2), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were evaluated on three occasions (baseline, and 4 and 8 weeks after commencement of the treatment paradigm). Extrapyramidal symptoms (EPS) and clinical symptoms were assessed using the Simpson-Angus scale and the Positive and Negative Syndrome Scale (PANSS), respectively. Results: Of the 60 subjects who were enrolled, 48 completed the study (n = 14, 13, 11, and 10 in the bromocriptine 2.5 mg/day, 5 mg/day, and 10 mg/day, and placebo groups, respectively). Four patients in the 10-mg/day group, two in the 5-mg/day group, and one in the placebo group resumed menses during the study. The mean level of prolactin significantly decreased from baseline to week 4, and then plateaued, showing no significant change for the remaining 4 weeks of the study. No significant changes in LH, FSH, or E2 levels were observed throughout the 8-week study period, either within or between groups. Conclusion: Administration of bromocriptine is a safe method for treating antipsychotic-drug-induced hyperprolactinemia without exacerbating either psychotic symptoms or EPS.

AB - Aim: The objective of the present study was to assess the efficacy and safety of bromocriptine treatment for patients with antipsychotic-drug-induced hyperprolactinemia in clinical practice. Methods: This was an 8-week randomized, single-blind, placebo-controlled, multicenter study. Sixty female schizophrenia patients were enrolled and were randomly assigned to one of four treatment groups: bromocriptine 2.5 mg/day, 5 mg/day, 10 mg/day, and placebo. Serum levels of prolactin, estradiol (E2), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were evaluated on three occasions (baseline, and 4 and 8 weeks after commencement of the treatment paradigm). Extrapyramidal symptoms (EPS) and clinical symptoms were assessed using the Simpson-Angus scale and the Positive and Negative Syndrome Scale (PANSS), respectively. Results: Of the 60 subjects who were enrolled, 48 completed the study (n = 14, 13, 11, and 10 in the bromocriptine 2.5 mg/day, 5 mg/day, and 10 mg/day, and placebo groups, respectively). Four patients in the 10-mg/day group, two in the 5-mg/day group, and one in the placebo group resumed menses during the study. The mean level of prolactin significantly decreased from baseline to week 4, and then plateaued, showing no significant change for the remaining 4 weeks of the study. No significant changes in LH, FSH, or E2 levels were observed throughout the 8-week study period, either within or between groups. Conclusion: Administration of bromocriptine is a safe method for treating antipsychotic-drug-induced hyperprolactinemia without exacerbating either psychotic symptoms or EPS.

KW - Amenorrhea

KW - Antipsychotics

KW - Bromocriptine

KW - Hyperprolactinemia

KW - Prolactin

UR - http://www.scopus.com/inward/record.url?scp=75649152404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75649152404&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1819.2009.02032.x

DO - 10.1111/j.1440-1819.2009.02032.x

M3 - Article

VL - 64

SP - 19

EP - 27

JO - Psychiatry and Clinical Neurosciences

JF - Psychiatry and Clinical Neurosciences

SN - 1323-1316

IS - 1

ER -